Drug Profile
Research programme : macrocyclic peptide therapeutics - JCR/PeptiDream
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals; PeptiDream
- Class Drug conjugates; Macrocyclic compounds; Macrolides; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in CNS-disorders in Japan
- 10 May 2019 Research programme : macrocyclic peptide therapeutics - JCR/PeptiDream is available for licensing as of 10 May 2019. https://www.peptidream.com/
- 22 Feb 2016 PeptiDream and JCR Pharmaceuticals agree to co-develop CNS disorders therapeutics in Japan